10-QPeriod: Q1 FY2022

DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2022

Filed April 28, 2022For Securities:DXCM

Summary

DexCom, Inc. (DXCM) reported solid financial results for the first quarter ended March 31, 2022, demonstrating continued revenue growth and improved profitability. The company's revenue increased by 25% year-over-year, driven by strong demand for its continuous glucose monitoring (CGM) systems. This top-line growth translated into a significant 72% increase in net income, highlighting effective cost management and operational efficiency. Financially, Dexcom maintained a strong liquidity position with over $2.69 billion in cash, cash equivalents, and short-term marketable securities. The company's balance sheet remains robust, with total assets growing to $5.06 billion. Management's strategic investments in research and development and manufacturing are expected to fuel future growth, particularly with the upcoming G7 system. Despite some headwinds, such as increased cost of sales and operating expenses, Dexcom's performance indicates a positive trajectory and a commitment to expanding its market leadership in diabetes management technology.

Financial Highlights

52 data points
Beta

Revenue

$628.80M

63.3% Gross Margin

Net Income

$97.30M

15.5% Net Margin

EPS (Diluted)

$0.23

Total Assets

$5.06B

Cash & Equivalents

$717.10M

Free Cash Flow

-$30.60M

Financial Statements
Beta
Revenue$628.80M
Cost of Revenue$230.70M
Gross Profit$398.10M
R&D Expenses$135.90M
SG&A Expenses$218.90M
Operating Expenses$356.80M
Operating Income$41.30M
Interest Expense$3.70M
Net Income$97.30M
EPS (Basic)$0.25
EPS (Diluted)$0.23
Shares Outstanding (Basic)388.90M
Shares Outstanding (Diluted)428.70M

Key Highlights

  • 1Revenue increased by 25% to $628.8 million compared to the prior year period.
  • 2Net income surged by 72% to $97.3 million, indicating improved profitability.
  • 3Gross profit margin stood at 63.3%, demonstrating strong control over cost of sales relative to revenue.
  • 4Operating income saw a slight decrease of 10% to $41.3 million, largely due to increased operating expenses.
  • 5Cash flow from operations was a robust $71.0 million, reflecting healthy cash generation from core business activities.
  • 6The company maintained a strong liquidity position with $2.69 billion in cash, cash equivalents, and short-term marketable securities at the end of the quarter.
  • 7Research and Development expenses increased by 24% to $135.9 million, signaling continued investment in innovation and future products.

Frequently Asked Questions

Dexcom's revenue growth of 25% was primarily driven by an increase in sales volume of its disposable sensors, attributed to the continued expansion of its global customer base. This was partially offset by shifts in product mix and pricing strategies related to its channel strategy.

Dexcom experienced a significant improvement in profitability, with net income increasing by 72% to $97.3 million in Q1 2022 compared to Q1 2021. This growth was driven by strong revenue performance, though partially offset by increased cost of sales and operating expenses.

Dexcom maintained a strong financial position, ending the quarter with $2.69 billion in cash, cash equivalents, and short-term marketable securities. The company reported positive cash flow from operations of $71.0 million and a healthy current ratio, indicating a solid ability to meet its short-term obligations.

The primary expense categories are Cost of Sales, Research and Development (R&D), and Selling, General, and Administrative (SG&A) expenses. In Q1 2022, Cost of Sales increased by 43% due to higher sales volume and inventory reserves. R&D expenses rose 24% driven by increased headcount and equipment costs. SG&A expenses grew 17% due to higher headcount, marketing initiatives, and other operational costs.